Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05394818 Active, not recruiting - Clinical trials for Advanced Solid Tumor

The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Start date: July 21, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label, phase I clinical trial of SHR-A2009 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

NCT ID: NCT05377528 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of AGEN1571 in Participants With Advanced Solid Tumors

Start date: July 19, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination with balstilimab (PD-1 inhibitor) and/or botensilimab (2-agent combination or 3-agent combination) in participants diagnosed with advanced solid tumors. Part 1 will be the dose escalation phase to determine the RP2D of AGEN1571 monotherapy or AGEN1571 in combination with balstilimab and/or botensilimab. Part 2 will be the dose expansion phase for specific disease indications. Participants will receive study treatment for up to 2 years, or until any disease progression, unacceptable toxicity, or participant wishes to withdraw consent for any reason.

NCT ID: NCT05300048 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Start date: April 22, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

NCT ID: NCT05226468 Active, not recruiting - Clinical trials for Advanced Solid Tumor

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Start date: April 25, 2022
Phase: Phase 1
Study type: Interventional

This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of NEI-01 and find out recommended dose of NEI-01 in solid tumor patient. Part 2: This part is extended dose design to determine the effectiveness of NEI-01 in in solid tumor and acute myeloid leukemia patients.

NCT ID: NCT05178888 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.

NCT ID: NCT05161390 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of LM-302 in Patients With Advance Solid Tumors

Start date: November 26, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

NCT ID: NCT05147350 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

MINOTAUR
Start date: August 9, 2022
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.

NCT ID: NCT05075564 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Start date: December 23, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-human, open-label, multicenter, non-randomized study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES002023 in patients with advanced solid tumors that are relapsed or refractory to standard therapies.

NCT ID: NCT05052268 Active, not recruiting - Clinical trials for Advanced Solid Tumor

XTX202 in Patients With Advanced Solid Tumors

Start date: January 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

NCT ID: NCT05021367 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor

Start date: September 23, 2021
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult patients with advanced solid tumors .The study was divided into phase Ia and phase Ib, Phase Ia: Dose escalation period, to evaluate the safety and tolerability of TQB3823 tablets, determine MTD;Phase Ib: Effectiveness exploration period, to expand the safe and effective dose group, and to recommend appropriate dosage and method for subsequent clinical research.